Farydak for Multiple myeloma (relapsed/refractory)
Quick answer: Farydak is used for Multiple myeloma (relapsed/refractory) as part of a histone deacetylase (hdac) inhibitor treatment regimen. Pan-HDAC inhibitor that induces cell-cycle arrest and apoptosis in malignant cells The specific dosing for Multiple myeloma (relapsed/refractory) is determined by your prescriber based on individual factors.
Why is Farydak used for Multiple myeloma (relapsed/refractory)?
Farydak belongs to the Histone deacetylase (HDAC) inhibitor class. Pan-HDAC inhibitor that induces cell-cycle arrest and apoptosis in malignant cells This action makes it useful for treating or managing Multiple myeloma (relapsed/refractory) in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Farydak is the right choice for a specific patient depends on the type and severity of Multiple myeloma (relapsed/refractory), response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Multiple myeloma (relapsed/refractory)
Common adult dosing range: 20 mg three times weekly in 21-day cycles. The actual dose for Multiple myeloma (relapsed/refractory) depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Farydak medicine page.
What to expect
Farydak treatment for Multiple myeloma (relapsed/refractory) typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Multiple myeloma (relapsed/refractory)
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Farydak is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Histone deacetylase (HDAC) inhibitor for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Farydak
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Farydak full prescribing information · All Histone deacetylase (HDAC) inhibitor alternatives
Frequently asked questions
How effective is Farydak for Multiple myeloma (relapsed/refractory)?
Effectiveness varies by individual response, dose, and severity. Farydak is one of several treatment options for Multiple myeloma (relapsed/refractory), supported by clinical evidence within the histone deacetylase (hdac) inhibitor class. Discuss expected response with your prescriber.
How long do I need to take Farydak for Multiple myeloma (relapsed/refractory)?
Treatment duration depends on the nature of Multiple myeloma (relapsed/refractory) — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Farydak when used for Multiple myeloma (relapsed/refractory)?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Farydak for Multiple myeloma (relapsed/refractory)?
Yes. Multiple medicines and non-drug options exist for Multiple myeloma (relapsed/refractory). Alternatives within the histone deacetylase (hdac) inhibitor class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.